The Liver Meeting

The Liver Meeting

Source:

Mayo M. Long-term safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC): 2-year results from a long-term study. Presented at: The Liver Meeting Digital Experience; Nov. 12-15, 2021 (virtual meeting).

Disclosures: Mayo reports study funding from CymaBay Therapeutics.
November 14, 2021
1 min watch
Save

VIDEO: Seladelpar improves markers of cholestasis in primary biliary cholangitis

Source:

Mayo M. Long-term safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC): 2-year results from a long-term study. Presented at: The Liver Meeting Digital Experience; Nov. 12-15, 2021 (virtual meeting).

Disclosures: Mayo reports study funding from CymaBay Therapeutics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In a video exclusive, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, reported long-term treatment with seladelpar was safe and well-tolerated in reducing markers of cholestasis and hepatocellular injury.

Mayo said seladelpar, overall, has “very safe and strong efficacy that gets even stronger in the second year.”